Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field
Identifieur interne : 000291 ( Main/Exploration ); précédent : 000290; suivant : 000292Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field
Auteurs : Polly Ambermoon [Australie] ; Adrian Carter [Australie] ; Wayne D. Hall [Australie] ; Nadeeka N. W. Dissanayaka [Australie] ; John D. O'Sullivan [Australie]Source :
- Addiction [ 0965-2140 ] ; 2011-02.
English descriptors
- KwdEn :
Abstract
Aims To describe the prevalence, phenomenology and correlates of ‘impulse control disorders’ (ICDs) in patients with Parkinson's disease (PD) treated with dopamine replacement therapy (DRT); to assess the strength of the evidence that DRT plays a contributory causal role in these disorders; and to highlight the implications of these disorders for research in the addiction field. Methods PubMed and Web of Science databases were searched and the reference lists of papers examined. Results The prevalence of ICDs in Parkinson's patients using DRT varied between 3.5% and 13.6%, depending on the severity and range of disorders assessed. PD patients with ICDs were: generally younger; had an earlier onset of PD; had a personal or family history of substance abuse or an ICD; and were more likely to be treated with dopamine receptor agonists (DA agonists) than levodopa (l‐dopa). There is reasonable evidence that dopaminergic medications play a causal role in ICDs in that they occur at a higher rate in an otherwise low‐risk population of adults, begin after initiation of DA agonist therapy and cease upon its discontinuation. A causal relationship is biologically plausible, but the role of other factors (such as concurrent mood disorders) remain to be clarified by better‐controlled studies. Conclusions Impulse control disorders among patients with Parkinson's disease receiving dopamine replacement therapy may provide a unique opportunity for addiction researchers to study the neurobiology of impulsive forms of behaviour (such as problem gambling) that appear to be caused, in part, by the therapeutic use of dopamine receptor agonists.
Url:
DOI: 10.1111/j.1360-0443.2010.03218.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field</title><author><name sortKey="Ambermoon, Polly" sort="Ambermoon, Polly" uniqKey="Ambermoon P" first="Polly" last="Ambermoon">Polly Ambermoon</name></author><author><name sortKey="Carter, Adrian" sort="Carter, Adrian" uniqKey="Carter A" first="Adrian" last="Carter">Adrian Carter</name></author><author><name sortKey="Hall, Wayne D" sort="Hall, Wayne D" uniqKey="Hall W" first="Wayne D." last="Hall">Wayne D. Hall</name></author><author><name sortKey="Dissanayaka, Nadeeka N W" sort="Dissanayaka, Nadeeka N W" uniqKey="Dissanayaka N" first="Nadeeka N. W." last="Dissanayaka">Nadeeka N. W. Dissanayaka</name></author><author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4CE84BAE539D3A0F9190551A4D76F5287C34B23D</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1360-0443.2010.03218.x</idno><idno type="url">https://api.istex.fr/document/4CE84BAE539D3A0F9190551A4D76F5287C34B23D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000361</idno><idno type="wicri:Area/Main/Curation">000310</idno><idno type="wicri:Area/Main/Exploration">000291</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field</title><author><name sortKey="Ambermoon, Polly" sort="Ambermoon, Polly" uniqKey="Ambermoon P" first="Polly" last="Ambermoon">Polly Ambermoon</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>The University of Queensland, UQ Centre for Clinical Research</wicri:regionArea><wicri:noRegion>UQ Centre for Clinical Research</wicri:noRegion></affiliation></author><author><name sortKey="Carter, Adrian" sort="Carter, Adrian" uniqKey="Carter A" first="Adrian" last="Carter">Adrian Carter</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>The University of Queensland, UQ Centre for Clinical Research</wicri:regionArea><wicri:noRegion>UQ Centre for Clinical Research</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>The University of Melbourne, School of Psychological Sciences</wicri:regionArea><wicri:noRegion>School of Psychological Sciences</wicri:noRegion></affiliation></author><author><name sortKey="Hall, Wayne D" sort="Hall, Wayne D" uniqKey="Hall W" first="Wayne D." last="Hall">Wayne D. Hall</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>The University of Queensland, UQ Centre for Clinical Research</wicri:regionArea><wicri:noRegion>UQ Centre for Clinical Research</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>The University of Queensland, Queensland Brain Institute</wicri:regionArea><wicri:noRegion>Queensland Brain Institute</wicri:noRegion></affiliation></author><author><name sortKey="Dissanayaka, Nadeeka N W" sort="Dissanayaka, Nadeeka N W" uniqKey="Dissanayaka N" first="Nadeeka N. W." last="Dissanayaka">Nadeeka N. W. Dissanayaka</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>The University of Queensland, UQ Centre for Clinical Research</wicri:regionArea><wicri:noRegion>UQ Centre for Clinical Research</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston</wicri:regionArea><wicri:noRegion>Herston</wicri:noRegion></affiliation></author><author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston</wicri:regionArea><wicri:noRegion>Herston</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>The University of Queensland, Royal Brisbane Clinical School, School of Medicine</wicri:regionArea><wicri:noRegion>School of Medicine</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Addiction</title><idno type="ISSN">0965-2140</idno><idno type="eISSN">1360-0443</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-02">2011-02</date><biblScope unit="volume">106</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="283">283</biblScope><biblScope unit="page" to="293">293</biblScope></imprint><idno type="ISSN">0965-2140</idno></series><idno type="istex">4CE84BAE539D3A0F9190551A4D76F5287C34B23D</idno><idno type="DOI">10.1111/j.1360-0443.2010.03218.x</idno><idno type="ArticleID">ADD3218</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0965-2140</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Behavioural addictions</term><term>Parkinson's disease</term><term>dopamine agonists</term><term>gambling</term><term>hypersexuality</term><term>impulse control disorders</term><term>substance abuse</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aims To describe the prevalence, phenomenology and correlates of ‘impulse control disorders’ (ICDs) in patients with Parkinson's disease (PD) treated with dopamine replacement therapy (DRT); to assess the strength of the evidence that DRT plays a contributory causal role in these disorders; and to highlight the implications of these disorders for research in the addiction field. Methods PubMed and Web of Science databases were searched and the reference lists of papers examined. Results The prevalence of ICDs in Parkinson's patients using DRT varied between 3.5% and 13.6%, depending on the severity and range of disorders assessed. PD patients with ICDs were: generally younger; had an earlier onset of PD; had a personal or family history of substance abuse or an ICD; and were more likely to be treated with dopamine receptor agonists (DA agonists) than levodopa (l‐dopa). There is reasonable evidence that dopaminergic medications play a causal role in ICDs in that they occur at a higher rate in an otherwise low‐risk population of adults, begin after initiation of DA agonist therapy and cease upon its discontinuation. A causal relationship is biologically plausible, but the role of other factors (such as concurrent mood disorders) remain to be clarified by better‐controlled studies. Conclusions Impulse control disorders among patients with Parkinson's disease receiving dopamine replacement therapy may provide a unique opportunity for addiction researchers to study the neurobiology of impulsive forms of behaviour (such as problem gambling) that appear to be caused, in part, by the therapeutic use of dopamine receptor agonists.</div></front></TEI><affiliations><list><country><li>Australie</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Ambermoon, Polly" sort="Ambermoon, Polly" uniqKey="Ambermoon P" first="Polly" last="Ambermoon">Polly Ambermoon</name></noRegion><name sortKey="Carter, Adrian" sort="Carter, Adrian" uniqKey="Carter A" first="Adrian" last="Carter">Adrian Carter</name><name sortKey="Carter, Adrian" sort="Carter, Adrian" uniqKey="Carter A" first="Adrian" last="Carter">Adrian Carter</name><name sortKey="Dissanayaka, Nadeeka N W" sort="Dissanayaka, Nadeeka N W" uniqKey="Dissanayaka N" first="Nadeeka N. W." last="Dissanayaka">Nadeeka N. W. Dissanayaka</name><name sortKey="Dissanayaka, Nadeeka N W" sort="Dissanayaka, Nadeeka N W" uniqKey="Dissanayaka N" first="Nadeeka N. W." last="Dissanayaka">Nadeeka N. W. Dissanayaka</name><name sortKey="Hall, Wayne D" sort="Hall, Wayne D" uniqKey="Hall W" first="Wayne D." last="Hall">Wayne D. Hall</name><name sortKey="Hall, Wayne D" sort="Hall, Wayne D" uniqKey="Hall W" first="Wayne D." last="Hall">Wayne D. Hall</name><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000291 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000291 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4CE84BAE539D3A0F9190551A4D76F5287C34B23D
|texte= Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field
}}
| This area was generated with Dilib version V0.6.23. |  |